arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

X4 Pharmaceuticals, Inc

XFOR
$4.62 ▲ +0.46 (+11.04%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
39 Visible periods
30 Metrics
Peer-ranked Benchmarks
Price Chart
25
Health
Poor
Bearish
auto_awesome

Analytical Summary

X4 Pharmaceuticals, Inc faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $583.5M
Dividend Yield
Revenue Growth -90.6%
Op. Margin None
ROIC -8.3%
FCF / Share $-0.16
Trailing P/E
Price / Book 2.6x
FCF Yield
Debt / Equity 0.45
info Valuation on last close. End-of-day price, Aug 7, 2026.

39-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$2.71M
↓ -90.6%
Net Income Profit after all expenses
$-20.24M
↑ +15.4%
Operating Margin Operating profit as % of sales
-32.8%
↑ +90.7% 0th
FCF / Share Free cash flow per share
$-0.16
↑ +91.4%
Long-Term Debt Long-term obligations
$75.00M
— 0.0%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability
1
Returns
18
Financial Health
43
Cash Quality
69

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 11 years · 39 quarters